Pfizer (PFE) Tops Q1 EPS by 29c, Beats on Revenue; Offers FY24 Guidance

Pfizer (NYSE: PFE) reported Q1 EPS of $0.82, $0.29 better than the analyst estimate of $0.53. Revenue for the quarter came in at $14.9 billion versus the consensus estimate of $14.04 billion.

GUIDANCE:

Pfizer sees FY2024 EPS of $2.15-$2.35, versus the consensus of $2.21. Pfizer sees FY2024 revenue of $58.5-61.5 billion, versus the consensus of $60 billion.

For earnings history and earnings-related data on Pfizer (PFE) click here.

You May Also Be Interested In

• Pfizer's Litfulo meets Phase 3 endpoints for vitiligo treatment
• Integra LifeSciences stock tumbles after cutting 2026 outlook
• Micron Technology (MU) Tops Q4 EPS by $2.26, Offers Guidance